Skip to main content

Table 6 Uncertainty estimates around key outputs

From: Modeling the potential economic benefits of an oral SARS-CoV-2 vaccine during an outbreak of COVID-19

 

5% Lower Bound

95% Upper Bound

All Variants

Cases Averted Scenario 1

1,690,073

3,925,199

Cases Averted Scenario 2

8,220,112

10,741,490

Omicron Variant

Cases Averted Scenario 1

1,507,559

3,495,682

Cases Averted Scenario 2

7,245,243

9,482,724

All Variants

Total Costs Averted Scenario 1

$2,438,601,000

$5,585,059,000

Total Costs Averted Scenario 2

$3,117,132,000

$6,495,989,000

Omicron Variant

Total Costs Averted Scenario 1

$2,030,328,000

$4,656,985,000

Total Costs Averted Scenario 2

$2,577,641,000

$5,390,628,000